Healthcare >> CEO Interviews >> April 6, 2009
JOHN CHEE KUEN HUI is Chief Technology Officer, Senior Vice President and Vice
Chairman, Board of Directors of Vasomedical, Inc. He has over 30 years of
experience in the technology and medical fields, including more than 14 years at
Vasomedical, Inc., a world leader in the design and development of enhanced
external counterpulsation (EECP) systems. Prior to Vasomedical, he was President
and CEO of Vasogenics, a company that first introduced EECP technology, a
noninvasive treatment of cardiovascular disease, to the commercial world. Dr.
Hui has published more than 60 clinical and scientific papers and he also holds
six patents. He also remains actively involved in the education field. He is an
Assistant Professor with the Department of Medicine (Cardiology Division) and
the Department of Surgery at the State University of New York at Stony Brook,
New York. He is also a research scientist in Brookhaven National Laboratory.
After graduating with a BA in Physics from International Christian University,
Tokyo, Japan in 1969, he spent a year at the University of California, Berkeley
before moving to the State University of New York, Stony Brook where he obtained
his Master's degree in 1972 and his Doctorate in 1975. During his graduate
research period in the thermodynamics of solids, Dr. Hui studied at the
Cavendish Laboratories at Cambridge University in the United Kingdom. Dr. Hui is
a leading authority on counterpulsation techniques, having studied the subject
with Clifford Birtwell, the inventor of the concept of counterpulsation, from
1974 until Dr. Birtwell's death in 1978, and carried on Dr. Birtwell's
experimental work at Stony Brook. Profile
picture of the things you're doing now.
Dr. Hui: Vasomedical, Inc., started in 1992. I had just finished my PhD in
